Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Cardiac Amyloidosis Determines the Prognosis of Systemic Amyloidosis; Roles and Responsibilities of Cardiologist

  • Lee, Ga Yeon (Division of Cardiology, Department of Medicine, Cardiac and Vascular Center, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jeon, Eun-Seok (Division of Cardiology, Department of Medicine, Cardiac and Vascular Center, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Published : 2013.11.30
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Falk RH. Cardiac amyloidosis: a treatable disease, often overlooked. Circulation 2011;124:1079-85. https://doi.org/10.1161/CIRCULATIONAHA.110.010447
  2. Kapoor P, Thenappan T, Singh E, Kumar S, Greipp PR. Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med 2011; 124:1006-15. https://doi.org/10.1016/j.amjmed.2011.04.013
  3. Lee MH, Lee SP, Kim YJ, Sohn DW. Incidence, diagnosis and prognosis of cardiac amyloidosis. Korean Circ J 2013;43:752-60. https://doi.org/10.4070/kcj.2013.43.11.752
  4. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 2010;3:155-64. https://doi.org/10.1016/j.jcmg.2009.09.023
  5. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and Nterminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-7. https://doi.org/10.1200/JCO.2004.03.029
  6. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989-95. https://doi.org/10.1200/JCO.2011.38.5724
  7. Lehrke S, Steen H, Kristen AV, et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis. Amyloid 2009;16:187-95. https://doi.org/10.3109/13506120903421538
  8. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5. https://doi.org/10.1161/01.CIR.0000068314.02595.B2
  9. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541-9. https://doi.org/10.1200/JCO.2011.37.7614
  10. Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev 2012;26:137-54. https://doi.org/10.1016/j.blre.2012.03.001